Breast cancer prevention in high-risk women
- PMID: 31862315
- DOI: 10.1016/j.bpobgyn.2019.11.006
Breast cancer prevention in high-risk women
Abstract
Women at high risk of developing breast cancer are a heterogeneous group of women including those with and without high-risk germline mutation/s. Prevention in these women requires a personalised and multidisciplinary approach. Preventive therapy with selective oestrogen receptor modulators (SERMs) like tamoxifen and aromatase inhibitors (AIs) substantially reduces breast cancer risk well beyond the active treatment period. The importance of benign breast disease as a marker of increased breast cancer risk remains underappreciated, and although the benefit of preventive therapy may be greater in such women, preventive therapy remains underutilised in these and other high-risk women. Bilateral Risk-Reducing Mastectomy (BRRM) reduces the risk of developing breast cancer by 90% in high-risk women such as carriers of BRCA mutations. It also improves breast cancer-specific survival in BRCA1 carriers. Bilateral risk-reducing salpingo-oophorectomy may also reduce risk in premenopausal BRCA2 carriers. Further research to improve risk models, to identify surrogate biomarkers of preventive therapy benefit and to develop newer preventive agents is needed.
Keywords: Bilateral risk-reducing mastectomy; Bilateral risk-reducing salpingo-oophorectomy; Breast cancer; Germline mutations; Prevention; SERMs.
Copyright © 2019. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest None.
Similar articles
-
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.Ann Ital Chir. 2019;90:1-2. Ann Ital Chir. 2019. PMID: 30872561
-
Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.JAMA. 2019 Jan 1;321(1):27. doi: 10.1001/jama.2018.18942. JAMA. 2019. PMID: 30521006 No abstract available.
-
Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.Int J Cancer. 2004 Nov 10;112(3):357-64. doi: 10.1002/ijc.20429. Int J Cancer. 2004. PMID: 15382059 Review.
-
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.Int J Cancer. 2008 May 1;122(9):2017-22. doi: 10.1002/ijc.23340. Int J Cancer. 2008. PMID: 18196574 Free PMC article.
-
Risk-reducing mastectomy for the prevention of primary breast cancer.Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD002748. doi: 10.1002/14651858.CD002748.pub4. Cochrane Database Syst Rev. 2018. PMID: 29620792 Free PMC article. Review.
Cited by
-
A Regulatory Network Analysis of the Importance of USP15 in Breast Cancer Metastasis and Prognosis.J Oncol. 2022 Sep 29;2022:1427726. doi: 10.1155/2022/1427726. eCollection 2022. J Oncol. 2022. PMID: 36213818 Free PMC article.
-
Participation in a High-Risk Program Is Associated with a Diagnosis of Earlier-Stage Disease Among Women at Increased Risk for Breast Cancer Development.Ann Surg Oncol. 2024 Oct;31(10):6764-6773. doi: 10.1245/s10434-024-15633-x. Epub 2024 Jun 29. Ann Surg Oncol. 2024. PMID: 38949720
-
Novel roles of PIWI proteins and PIWI-interacting RNAs in human health and diseases.Cell Commun Signal. 2023 Nov 29;21(1):343. doi: 10.1186/s12964-023-01368-x. Cell Commun Signal. 2023. PMID: 38031146 Free PMC article. Review.
-
Penetrating Exploration of Prognostic Correlations of the FKBP Gene Family with Lung Adenocarcinoma.J Pers Med. 2022 Dec 26;13(1):49. doi: 10.3390/jpm13010049. J Pers Med. 2022. PMID: 36675710 Free PMC article.
-
Effects of Out-of-Hospital Continuous Nursing on Postoperative Breast Cancer Patients by Medical Big Data.J Healthc Eng. 2022 Jan 6;2022:9506915. doi: 10.1155/2022/9506915. eCollection 2022. J Healthc Eng. 2022. PMID: 35035864 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
